-
公开(公告)号：US20100292414A1
公开(公告)日：2010-11-18
申请号：US12678620
申请日：2008-09-26
IPC分类号： A61K47/48
CPC分类号： A61K31/785 , A61K47/60 , A61K47/645
摘要： Enzymes in the body vary among different species, and also vary among individuals of the same species. Thus, it has been demanded to develop a novel steroid-containing pharmaceutical preparation which can release a drug in a manner independent of the enzymes present in the body, and which is expected to have an efficacious therapeutic effect.Disclosed is a high-molecular weight conjugate of a steroid, comprising a structure in which a carboxylic acid group of a polymer having a polyethylene glycol moiety and a succinic acid monoamide moiety having two or more succinic acid monoamide units is ester-bonded to a hydroxy group in the steroid.
摘要翻译： 身体中的酶在不同的物种中不同，并且在同一物种的个体中也是不同的。 因此，已经要求开发一种能够以与体内存在的酶无关的方式释放药物的新型类固醇药物制剂，其预期具有有效的治疗效果。 公开了类固醇的高分子量缀合物，其包含其中具有聚乙二醇部分的聚合物的羧酸基团和具有两个或多个琥珀酸单酰胺单元的琥珀酸单酰胺部分与羟基酯键合的结构 在类固醇组。
-
公开(公告)号：US20100165303A1
公开(公告)日：2010-07-01
申请号：US12654287
申请日：2009-12-16
申请人： Toshitaka Murata , Ryusaku Takahashi , Masahiko Miyake , Manabu Kobayashi , Takatsugu Aizaki , Hironobu Fukutomi
发明人： Toshitaka Murata , Ryusaku Takahashi , Masahiko Miyake , Manabu Kobayashi , Takatsugu Aizaki , Hironobu Fukutomi
摘要： A screen assembly and a rear-projection type graphic display device are provided to block overscanned light Lo projected outside a fresnel lens screen. The screen assembly 20A includes the fresnel lens screen 21, a screen retainer 22 and a light blocking member 23. The fresnel lens screen 21 forms an image on the side of a front surface 21b by image light Le incoming through a back surface 21a. The screen retainer 22 has a back surface 22a whose area is larger than the back surface 21a and the front surface 21b and which is opposed to the front surface 21b to hold it, and a front surface 22b located on opposite side of the back surface 22a to allow an image formed by the image light incoming through the back surface 21a to be visible through the front surface 22b. The screen retainer 22 has an optical transparency. The light blocking member 23 is arranged so as to surround respective side surfaces of the screen 21 in the form of a frame. At least part of the light blocking member 23 is arranged so as to project to the side of the back surface 21a of the screen.
摘要翻译： 提供了屏幕组件和背投式图形显示装置，以阻挡投射在菲涅尔透镜屏幕外部的过扫描光线Lo。 屏幕组件20A包括菲涅尔透镜屏幕21，屏幕保持器22和遮光构件23.菲涅尔透镜屏幕21通过背面21a进入的图像光Le形成在前表面21b侧的图像。 屏幕保持器22具有面积大于后表面21a和前表面21b并且与前表面21b相对以保持它的后表面22a，并且位于背表面22a的相对侧上的前表面22b 以允许通过后表面21a进入的图像光形成的图像通过前表面22b可见。 屏幕保持器22具有光学透明度。 遮光构件23被布置成围绕框架的形式的屏幕21的各个侧表面。 遮光构件23的至少一部分配置成向屏幕的背面21a侧突出。
-
3.发明申请Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer 有权含微水溶性抗癌剂和新型嵌段共聚物的胶束制剂公开(公告)号：US20090156742A1
公开(公告)日：2009-06-18
申请号：US12322322
申请日：2009-01-30
IPC分类号： C08L53/00
CPC分类号： A61K9/1075 , A61K31/337 , A61K47/42
摘要： A novel micellar preparation in which the solubility of a sparingly water-soluble anticancer agent has been heightened and which after intravenous administration, enables a high blood concentration to be maintained. The preparation has high medicinal activity and/or is reduced in side effects. The micellar preparation is formed from a block copolymer represented by the following general formula (1): [wherein R1 represents hydrogen or C1-5 alkyl; R2 represents C1-5 alkylene; R3 represents methylene or ethylene; R4 represents hydrogen or C1-4 acyl; R5 represents hydroxyl, optionally substituted aryl C2-8 alkoxyl, substituted C1-4 alkylamino, or amino having a residue of either an amino acid or a peptide derivative; n is an integer of 5 to 1,000; m is an integer of 2 to 300; and x is an integer of 1 to 300; provided that the proportion of hydroxy in the R5's is 0 to 99% and x is not larger than m] and a sparingly water-soluble anticancer agent.
摘要翻译： 提高了微水溶性抗癌剂的溶解性的新型胶束制剂，并且在静脉内给药后能够维持高血药浓度。 该制剂具有高药用活性和/或副作用减少。 胶束制剂由下列通式（1）表示的嵌段共聚物形成：[其中R 1表示氢或C 1-5烷基; R2表示C1-5亚烷基; R3表示亚甲基或亚乙基; R4代表氢或C1-4酰基; R5表示羟基，任选取代的芳基C2-8烷氧基，取代的C1-4烷基氨基或具有氨基酸或肽衍生物残基的氨基; n为5〜1000的整数。 m为2〜300的整数， x为1〜300的整数。 条件是R5中羟基的比例为0-99％且x不大于m]和少量水溶性抗癌剂。
-
4.发明申请Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer 审中-公开含微水溶性抗癌剂和新型嵌段共聚物的胶束制剂公开(公告)号：US20060099265A1
公开(公告)日：2006-05-11
申请号：US10548998
申请日：2004-03-18
IPC分类号： A61K9/14
CPC分类号： A61K9/1075 , A61K31/337 , A61K47/42
摘要： A novel micellar preparation in which the solubility of a sparingly water-soluble anticancer agent has been heightened and which after intravenous administration, enables a high blood concentration to be maintained. The preparation has high medicinal activity and/or is reduced in side effects. The micellar preparation is formed from a block copolymer represented by the following general formula (1): [wherein R1 represents hydrogen or C1-5 alkyl; R2 represents C1-5 alkylene; R3 represents methylene or ethylene; R4 represents hydrogen or C1-4 acyl; R5 represents hydroxyl, optionally substituted aryl C2-8 alkoxyl, substituted C1-4 alkylamino, or amino having a residue of either an amino acid or a peptide derivative; n is an integer of 5 to 1,000; m is an integer of 2 to 300; and x is an integer of 1 to 300; provided that the proportion of hydroxy in the R5's is 0 to 99% and x is not larger than m] and a sparingly water-soluble anticancer agent.
摘要翻译： 提高了微水溶性抗癌剂的溶解性的新型胶束制剂，并且在静脉内给药后能够维持高血药浓度。 该制剂具有高药用活性和/或副作用减少。 胶束制剂由以下通式（1）表示的嵌段共聚物形成：[其中R 1表示氢或C 1-5烷基; R 2表示C 1-5亚烷基; R3表示亚甲基或亚乙基; R 4表示氢或C 1-4 - 酰基; R5表示羟基，任选取代的芳基C 2-8烷氧基，取代的C 1-4烷基氨基或具有氨基酸或肽衍生物残基的氨基; n为5〜1000的整数。 m为2〜300的整数， x为1〜300的整数。 条件是R5中羟基的比例为0-99％且x不大于m]和少量水溶性抗癌剂。
-
公开(公告)号：US08388147B2
公开(公告)日：2013-03-05
申请号：US12654287
申请日：2009-12-16
申请人： Toshitaka Murata , Ryusaku Takahashi , Masahiko Miyake , Manabu Kobayashi , Takatsugu Aizaki , Hironobu Fukutomi
发明人： Toshitaka Murata , Ryusaku Takahashi , Masahiko Miyake , Manabu Kobayashi , Takatsugu Aizaki , Hironobu Fukutomi
IPC分类号： G03B21/14
摘要： A screen assembly and a rear-projection type graphic display device are provided to block overscanned light Lo projected outside a fresnel lens screen. The screen assembly 20A includes the fresnel lens screen 21, a screen retainer 22 and a light blocking member 23. The fresnel lens screen 21 forms an image on the side of a front surface 21b by image light Le incoming through a back surface 21a. The screen retainer 22 has a back surface 22a whose area is larger than the back surface 21a and the front surface 21b and which is opposed to the front surface 21b to hold it, and a front surface 22b located on opposite side of the back surface 22a to allow an image formed by the image light incoming through the back surface 21a to be visible through the front surface 22b. The screen retainer 22 has an optical transparency. The light blocking member 23 is arranged so as to surround respective side surfaces of the screen 21 in the form of a frame. At least part of the light blocking member 23 is arranged so as to project to the side of the back surface 21a of the screen.
摘要翻译： 提供了屏幕组件和背投式图形显示装置，以阻挡投射在菲涅尔透镜屏幕外部的过扫描光线Lo。 屏幕组件20A包括菲涅尔透镜屏幕21，屏幕保持器22和遮光构件23.菲涅耳透镜屏幕21通过背面21a进入的图像光Le形成在前表面21b侧的图像。 屏幕保持器22具有面积大于后表面21a和前表面21b并且与前表面21b相对以保持它的后表面22a，并且位于背表面22a的相对侧上的前表面22b 以允许通过后表面21a进入的图像光形成的图像通过前表面22b可见。 屏幕保持器22具有光学透明度。 遮光构件23被布置成围绕框架的形式的屏幕21的各个侧表面。 遮光构件23的至少一部分配置成向屏幕的背面21a侧突出。
-
公开(公告)号：US08337025B2
公开(公告)日：2012-12-25
申请号：US12458991
申请日：2009-07-29
申请人： Manabu Kobayashi , Ryusaku Takahashi , Toshitaka Murata , Takatsugu Aizaki , Masahiko Miyake , Hironobu Fukutomi
发明人： Manabu Kobayashi , Ryusaku Takahashi , Toshitaka Murata , Takatsugu Aizaki , Masahiko Miyake , Hironobu Fukutomi
CPC分类号： H04N5/7416 , H04N9/3147 , H04N9/3185 , H04N21/42204 , H04N21/4316 , H04N21/47
摘要： A projection type display device includes a image displaying element having image display areas for displaying a plurality of images respectively, a projection optical system having an emitting part for emitting projection light flux to the image display areas of the image displaying element, and a plurality of screens for displaying projected images by the projection light flux transmitted through the image display areas of the image displaying element. In the projection type display device, the image display areas are formed in respective areas in the image displaying element independent of each other. The projected images on the screens correspond to the image display areas, respectively. Each of the screens is arranged in such a position that the each of the screens is not overlapped with shadows of the other screens which are produced since the projection light flux is emitted from the emitting part to the screens.
摘要翻译： 一种投影型显示装置，包括具有用于分别显示多个图像的图像显示区域的图像显示元件，具有用于向图像显示元件的图像显示区域发射投影光通量的发射部分的投影光学系统，以及多个 用于通过传输通过图像显示元件的图像显示区域的投影光通量来显示投影图像的屏幕。 在投影型显示装置中，图像显示区域彼此独立地形成在图像显示元件的各个区域中。 屏幕上的投影图像分别对应于图像显示区域。 每个屏幕布置在这样的位置，即每个屏幕不与由于投影光通量从发光部分发射到屏幕而产生的其它屏幕的阴影重叠。
-
公开(公告)号：USD618268S1
公开(公告)日：2010-06-22
申请号：US29311038
申请日：2008-12-12
-
公开(公告)号：US08703878B2
公开(公告)日：2014-04-22
申请号：US12678620
申请日：2008-09-26
IPC分类号： A61K47/48
CPC分类号： A61K31/785 , A61K47/60 , A61K47/645
摘要： Enzymes in the body vary among different species, and also vary among individuals of the same species. Thus, it has been demanded to develop a novel steroid-containing pharmaceutical preparation which can release a drug in a manner independent of the enzymes present in the body, and which is expected to have an efficacious therapeutic effect.Disclosed is a high-molecular weight conjugate of a steroid, comprising a structure in which a carboxylic acid group of a polymer having a polyethylene glycol moiety and a succinic acid monoamide moiety having two or more succinic acid monoamide units is ester-bonded to a hydroxy group in the steroid.
摘要翻译： 身体中的酶在不同的物种中不同，并且在同一物种的个体中也是不同的。 因此，已经要求开发一种能够以与体内存在的酶无关的方式释放药物的新型类固醇药物制剂，其预期具有有效的治疗效果。 公开了类固醇的高分子量缀合物，其包含其中具有聚乙二醇部分的聚合物的羧酸基团和具有两个或多个琥珀酸单酰胺单元的琥珀酸单酰胺部分与羟基酯键合的结构 在类固醇组。
-
公开(公告)号：US06251355B1
公开(公告)日：2001-06-26
申请号：US09319837
申请日：1999-06-10
申请人： Toshitaka Murata , Keizou Ishikawa , Osamu Kogawa , Kenji Iwata
发明人： Toshitaka Murata , Keizou Ishikawa , Osamu Kogawa , Kenji Iwata
IPC分类号： C01B2100
CPC分类号： C01G55/002 , A61K9/14 , A61K33/24 , C01P2002/72 , C01P2002/74 , C01P2004/03
摘要： The present invention relates to a novel fine cisplatin powder utilized as an anticancer agent. The fine cisplatin powder obtained in the present invention does not cause secondary agglomeration, is excellent in fluidity and easily handleable in the pharmaceutical preparation step. Furthermore, the fine cisplatin powder is reduced in the content of N,N-dimethylformamide as the residual solvent, and can be dissolved rapidly in physiological saline, thus being suitable for cancer therapy particularly by intra-arterial injection. This fine powder can be produced by contriving specified means for crystallizing cisplatin from a solution thereof in N,N-dimethylformamide.
摘要翻译： 本发明涉及用作抗癌剂的新颖的顺铂铂粉。 本发明得到的细顺铂粉末不会引起二次凝聚，流动性优异，药物制备工序容易操作。 此外，顺铂的细粉末作为残留溶剂的N，N-二甲基甲酰胺的含量降低，能够迅速溶解于生理盐水中，因此特别适用于动脉内注射的癌症治疗。 这种细粉末可以通过设计用于在N，N-二甲基甲酰胺中从其溶液中结晶顺铂的特定方法来制备。
-
10.发明授权Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer 有权含微水溶性抗癌剂和新型嵌段共聚物的胶束制剂公开(公告)号：US07820759B2
公开(公告)日：2010-10-26
申请号：US12322322
申请日：2009-01-30
IPC分类号： A61K47/48
CPC分类号： A61K9/1075 , A61K31/337 , A61K47/42
摘要： A novel micellar preparation in which the solubility of a sparingly water-soluble anticancer agent has been heightened and which after intravenous administration, enables a high blood concentration to be maintained. The preparation has high medicinal activity and/or is reduced in side effects. The micellar preparation is formed from a block copolymer represented by the following general formula (1): [wherein R1 represents hydrogen or C1-5 alkyl; R2 represents C1-5 alkylene; R3 represents methylene or ethylene; R4 represents hydrogen or C1-4 acyl; R5 represents hydroxyl, optionally substituted aryl C2-8 alkoxyl, substituted C1-4 alkylamino, or amino having a residue of either an amino acid or a peptide derivative; n is an integer of 5 to 1,000; m is an integer of 2 to 300; and x is an integer of 1 to 300; provided that the proportion of hydroxy in the R5's is 0 to 99% and x is not larger than m] and a sparingly water-soluble anticancer agent.
摘要翻译： 提高了微水溶性抗癌剂的溶解性的新型胶束制剂，并且在静脉内给药后能够维持高血药浓度。 该制剂具有高药用活性和/或副作用减少。 胶束制剂由下列通式（1）表示的嵌段共聚物形成：[其中R 1表示氢或C 1-5烷基; R2表示C1-5亚烷基; R3表示亚甲基或亚乙基; R4代表氢或C1-4酰基; R5表示羟基，任选取代的芳基C2-8烷氧基，取代的C1-4烷基氨基或具有氨基酸或肽衍生物残基的氨基; n为5〜1000的整数。 m为2〜300的整数， x为1〜300的整数。 条件是R5中羟基的比例为0-99％且x不大于m]和少量水溶性抗癌剂。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.016 秒)